公开(公告)号：US6033364A

公开(公告)日：2000-03-07

申请号：US966848

申请日：1997-11-07

申请人： E. Magnus Ohman ,  Robert H. Christenson ,  Robert M. Califf ,  Mary Ann O'Hanesian ,  Kristina N. Sigmon

发明人： E. Magnus Ohman ,  Robert H. Christenson ,  Robert M. Califf ,  Mary Ann O'Hanesian ,  Kristina N. Sigmon

IPC分类号： C12Q1/50 ,  G01N33/68 ,  G06F17/00 ,  G06F19/00 ,  A61B5/00

CPC分类号： C12Q1/50 ,  G01N33/6887 ,  G06F19/3487

摘要： The present invention is a method of diagnosing the presence of a persistent occlusion in a myocardial infarct patient undergoing thrombolytic therapy. The method comprises detecting a series of five variables from the patient and then generating the probability of the presence of a persistent occlusion from those variables. The first variable comprises a serum creatine kinase MB (CK-MB) level from a patient at the onset of thrombolytic therapy. The second variable comprises a second CK-MB level in the patient at a predetermined time after the onset of thrombolytic therapy. The third variable comprises the presence or absence of chest pain a predetermined time after the onset of thrombolytic therapy. The fourth variable comprises the serum myoglobin level in the patient at a predetermined time after the onset of thrombolytic therapy. In a preferred embodiment of the present invention, the second, third and fourth variables are detected within 30 minutes of each other and within about 1 to about 3 hours after the initial variable is detected. In an alternate embodiment a fifth variable reflecting the time from onset of chest pain to the beginning of thrombolytic therapy is included in the regression model.

摘要翻译： 本发明是诊断经历溶栓治疗的心肌梗死患者中持续性闭塞的存在的方法。 该方法包括从患者中检测一系列五个变量，然后从这些变量产生持续闭塞的存在概率。 第一个变量包括来自溶栓治疗开始时患者的血清肌酸激酶MB（CK-MB）水平。 第二变量包括在溶栓治疗开始之后的预定时间的患者中的第二CK-MB水平。 第三个变量包括在溶栓治疗开始后的预定时间内存在或不存在胸痛。 第四个变量包括在溶栓治疗开始之后的预定时间内患者的血清肌红蛋白水平。 在本发明的优选实施例中，第二，第三和第四变量在彼此之间的30分钟内被检测，并且在检测到初始变量之后约1至约3小时内。 在替代实施例中，回归模型中包括反映从胸痛发作到溶栓治疗开始的时间的第五个变量。